All Names: Olaparib,Lynparza,Olanib,Olaparix,Lynib
Indications:1. First-Line Maintenance Treatment of BRCA-mutated Advanced Ovarian Cancer; 2. First-line Maintenance Treatment of HRD-positive Advanced Ovarian Cancer in Combination with Bevacizumab; 3. Maintenance Treatment of Recurrent Ovarian Cancer; 4. Advanced Germline BRCA-mutated Ovarian Cancer After 3 or More Lines of Chemotherapy; 5. Germline BRCA-mutated HER2-negative Metastatic Breast Cancer; 6. First-Line Maintenance Treatment of Germline BRCA-mutated Metastatic Pancreatic Adenocarcinoma; 7. HRR Gene-mutated Metastatic Castration-Resistant Prostate Cancer
Manufacturer:Everest Medicines, Bangladesh
Customs Clearance Procedure:If the customs requires the package for customs clearance, please pay the customs clearance fee according to the content of EMS SMS and customs regulations.
INDICATIONS AND USAGE(适应症)
First-Line Maintenance Treatment of BRCA-mutated Advanced Ovarian Cancer
Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.
First-line Maintenance Treatment of HRD-positive Advanced Ovarian Cancer in Combination with Bevacizumab
Lynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either:
a deleterious or suspected deleterious BRCA mutation, and/or
genomic instability.
Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.
Maintenance Treatment of Recurrent Ovarian Cancer
Lynparza is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy.
Advanced Germline BRCA-mutated Ovarian Cancer After 3 or More Lines of Chemotherapy
Lynparza is indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.
Germline BRCA-mutated HER2-negative Metastatic Breast Cancer
Lynparza is indicated for the treatment of adult patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.
First-Line Maintenance Treatment of Germline BRCA-mutated Metastatic Pancreatic Adenocarcinoma
Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.
HRR Gene-mutated Metastatic Castration-Resistant Prostate Cancer
Lynparza is indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.
DOSAGE(服用剂量)
The recommended dosage of Lynparza is 300 mg taken orally twice daily, with or without food.
If a patient misses a dose of Lynparza, instruct patient to take their next dose at its scheduled time.
Instruct patients to swallow tablets whole. Do not chew, crush, dissolve, or divide tablet.
First-Line Maintenance Treatment of BRCA-mutated Advanced Ovarian Cancer
Continue treatment until disease progression, unacceptable toxicity, or completion of 2 years of treatment. Patients with a complete response (no radiological evidence of disease) at 2 years should stop treatment. Patients with evidence of disease at 2 years, who in the opinion of the treating healthcare provider can derive further benefit from continuous treatment, can be treated beyond 2 years.
First-Line Maintenance Treatment of HRD-positive Advanced Ovarian Cancer in Combination with Bevacizumab
Continue Lynparza treatment until disease progression, unacceptable toxicity, or completion of 2 years of treatment. Patients with a complete response (no radiological evidence of disease) at 2 years should stop treatment. Patients with evidence of disease at 2 years, who in the opinion of the treating healthcare provider can derive further benefit from continuous Lynparza treatment, can be treated beyond 2 years.
When used with Lynparza, the recommended dose of bevacizumab is 15 mg/kg every three weeks. Bevacizumab should be given for a total of 15 months including the period given with chemotherapy and given as maintenance. Refer to the Prescribing Information for bevacizumab when used in combination with Lynparza for more information.
Recurrent Ovarian Cancer, Germline BRCAm Advanced Ovarian Cancer, HER2-negative Metastatic Breast Cancer, Metastatic Pancreatic Adenocarcinoma, and HRR Gene-mutated Metastatic Castration-Resistant Prostate Cancer
Continue treatment until disease progression or unacceptable toxicity for:
Maintenance treatment of recurrent ovarian cancer
Advanced germline BRCA-mutated ovarian cancer
Germline BRCA-mutated HER-2 negative metastatic breast cancer
First-line maintenance treatment of germline BRCA-mutated metastatic pancreatic adenocarcinoma.
HRR gene-mutated metastatic castration-resistant prostate cancer
Patients receiving Lynparza for mCRPC should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy.
ADVERSE REACTIONS(不良反应)
Myelodysplastic Syndrome/Acute Myeloid Leukemia
Pneumonitis
Venous Thromboembolic Events
For full information, please refer to:
https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/741ff3e3-dc1a-45a6-84e5-2481b27131aa/spl-doc?hl=Olaparib
Olanibinformation